VK2735 vs Tirzepatide
Two dual GIP/GLP-1 agonists at very different stages of development.
The short answer: Same receptor pair; VK2735 is earlier-stage and has an oral formulation in development.
VK2735
Tirzepatide
Compound in Mounjaro® · Zepbound®Side by side
| Property | VK2735 | Tirzepatide |
|---|---|---|
| Research category | Metabolic Research | Metabolic Research |
| Presentation | 5mg vial | 2.5mg × 4 pens |
| Dosage options | 5mg · 10mg · 20mg | 2.5mg × 4 pens · 5mg × 4 pens · 10mg × 4 pens · 15mg × 4 pens |
| Approved medicine using it | None — investigational | Mounjaro® · Zepbound® |
| Availability | In stock | In stock |
| Batch COA | Supplied with order | Supplied with order |
| From | €292.90 | €324.90 |
How they differ
VK2735 and tirzepatide both target the GIP and GLP-1 receptors, which puts them in the same mechanistic class — unusual in a catalogue where most comparisons hinge on differing receptor coverage.
The separation is developmental rather than mechanistic. Tirzepatide has completed its pivotal programmes and is marketed. VK2735 is in earlier trials, and notably is being developed in both subcutaneous and oral forms, which is uncommon for a peptide of this size.
For reference work, tirzepatide has far more published data to compare against; VK2735 has correspondingly little.
At the bench
Same receptor pair, same presentation, so the handling and the reconstitution maths are identical. What differs is how much you can check your work against — tirzepatide has a large published record, VK2735 comparatively little.
What this comparison does not settle
Sharing a receptor pair does not make two molecules equivalent. The balance of affinity between GIP and GLP-1 differs between them, and that balance is a design decision rather than a fixed property of the class.
Common questions
What is the difference between VK2735 and Tirzepatide?
Same receptor pair; VK2735 is earlier-stage and has an oral formulation in development. Two dual GIP/GLP-1 agonists at very different stages of development.
Is VK2735 or Tirzepatide better?
Neither, and the question does not have a general answer. They are compared here on mechanism rather than merit. Sharing a receptor pair does not make two molecules equivalent. The balance of affinity between GIP and GLP-1 differs between them, and that balance is a design decision rather than a fixed property of the class.
Which of the two has more published data?
Tirzepatide. It is the compound behind Mounjaro · Zepbound, so it carries a completed trial programme. VK2735 remains investigational.
For research use only. Not for human consumption, diagnostic, therapeutic or veterinary use. Brand names are trademarks of their respective owners and are referenced only to identify the active compound — no affiliation or equivalence is claimed.